1.
J Glob Antimicrob Resist
; 37: 190-194, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38588973
RESUMO
We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support. The in-hospital mortality rate was 24%. These data advance our understanding of real-world indications and outcomes of imipenem/cilastatin/relebactam use.